S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price, News & Analysis

$13.19
+0.21 (+1.62%)
(As of 09:39 AM ET)
Today's Range
$13.07
$13.40
50-Day Range
$10.80
$18.56
52-Week Range
$8.25
$28.44
Volume
10,734 shs
Average Volume
127,954 shs
Market Capitalization
$53.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.00

Precision BioSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
477.8% Upside
$75.00 Price Target
Short Interest
Healthy
4.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
-0.23mentions of Precision BioSciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$64,854 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.71) to ($6.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.22 out of 5 stars

Medical Sector

175th out of 939 stocks

Biological Products, Except Diagnostic Industry

22nd out of 156 stocks

DTIL stock logo

About Precision BioSciences Stock (NASDAQ:DTIL)

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Stock Price History

DTIL Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
Precision BioSciences Inc Q4 Loss decreases, but misses estimates
Earnings Preview: Precision BioSciences
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Precision BioSciences, Inc. (PBS0.F)
Precision BioSciences Sinks 30%; Sets $40 Mln Stock Offering
See More Headlines
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
115
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$75.00
High Stock Price Target
$90.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+477.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-111,640,000.00
Net Margins
-140.60%
Pretax Margin
-164.10%

Debt

Sales & Book Value

Annual Sales
$25.10 million
Book Value
$16.36 per share

Miscellaneous

Free Float
3,853,000
Market Cap
$52.70 million
Optionable
Optionable
Beta
1.56
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael Amoroso (Age 45)
    President, CEO & Director
    Comp: $979.04k
  • Mr. John Alexander Kelly R.Ph. (Age 57)
    CFO & Principal Accounting Officer
    Comp: $623.58k
  • Mr. Dario Scimeca (Age 48)
    General Counsel & Secretary
    Comp: $576.43k
  • Dr. Jefferson J. Smith Ph.D. (Age 51)
    Co-Founder & Chief Research Officer
  • Mei Burris
    Director of Investor Relations & Finance
  • Mr. Bruce Stevens
    Vice President of Quality & Compliance
  • Maurissa Messier
    Senior Director of Corporate Communications
  • Ms. Juli Blanche
    Chief People Officer
  • Mr. Garrett Gincley
    Head of Manufacturing
  • Dr. Alan F. List M.D. (Age 69)
    Chief Medical Officer

DTIL Stock Analysis - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DTIL shares.
View DTIL analyst ratings
or view top-rated stocks.

What is Precision BioSciences' stock price target for 2024?

2 analysts have issued 1 year price objectives for Precision BioSciences' shares. Their DTIL share price targets range from $60.00 to $90.00. On average, they predict the company's stock price to reach $75.00 in the next year. This suggests a possible upside of 477.8% from the stock's current price.
View analysts price targets for DTIL
or view top-rated stocks among Wall Street analysts.

How have DTIL shares performed in 2024?

Precision BioSciences' stock was trading at $10.95 at the start of the year. Since then, DTIL stock has increased by 18.5% and is now trading at $12.98.
View the best growth stocks for 2024 here
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) issued its earnings results on Wednesday, November, 10th. The company reported ($5.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($17.70) by $12.00. The company earned $24.04 million during the quarter, compared to analysts' expectations of $8.54 million. Precision BioSciences had a negative trailing twelve-month return on equity of 189.47% and a negative net margin of 140.60%. During the same quarter last year, the business posted ($15.00) EPS.

What ETF holds Precision BioSciences' stock?

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

When did Precision BioSciences' stock split?

Precision BioSciences shares reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital World Investors (4.20%), Vanguard Group Inc. (3.90%), Vanguard Group Inc. (117.11%), Blue Owl Capital Holdings LP (0.50%), Goldman Sachs Group Inc. (12.16%) and Corient Private Wealth LLC (0.19%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin.
View institutional ownership trends
.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DTIL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners